Related Experiment Videos
[Prostatic electrovaporization, a new treatment for prostatic hyperplasia]
A Santos García-Vaquero1, J A Chicharro Molero, M Ruíz Roldán
1Servicio de Urología, Hospital Regional, Málaga.
Actas Urologicas Espanolas
|July 1, 1997
Summary
Prostate electrovaporization offers a less invasive surgical option for benign prostatic hyperplasia (BPH). This technique shows promising results with reduced recovery time and costs compared to traditional transurethral resection (TUR).
Area of Science:
- Urology
- Minimally Invasive Surgery
- Surgical Technology
Background:
- Transurethral resection (TUR) is the standard surgical treatment for benign prostatic hyperplasia (BPH).
- While effective, TUR is associated with significant patient morbidity.
- Newer techniques, particularly laser procedures, aim to reduce surgical complications.
Purpose of the Study:
- To evaluate the preliminary outcomes of prostate electrovaporization for BPH management.
- To assess the efficacy and safety of electrovaporization compared to conventional TUR.
- To determine the feasibility and potential benefits of this novel technique.
Main Methods:
- A prospective study involving 75 patients undergoing prostate electrovaporization over a 5-month period.
- Efficacy was measured using the International Prostate Symptom Score (IPSS) and peak flow rate.
- Safety was assessed by monitoring complications, vesical catheter duration, and operating time.
Main Results:
- Mean hospital stay was 2 days, with an average operative time of 32 minutes.
- Post-operative vesical catheterization averaged 48 hours.
- At 3 months, patients showed a mean peak flow of 19.2 ml/sec and a mean IPSS of 7.
Conclusions:
- Prostate electrovaporization demonstrates a favorable preliminary safety and efficacy profile for BPH.
- The technique offers advantages such as quick convalescence, reduced costs, and ease of performance.
- Electrovaporization is a potential alternative to conventional TUR, warranting further long-term studies on histological effects.